

DIVERSITY

Drägerwerk AG & Co. KGaA
Conference call
Interim report January 1 to June 30, 2013

Lübeck, August 1, 2013

Disclaimer



This presentation does not constitute an offer of securities for sale or a solicitation of an offer to purchase any securities. No money, securities or other consideration is being solicited by this presentation.

This presentation contains forward-looking statements regarding the future development of the Dräger Group. These forward-looking statements are based on the current expectations, presumptions, and forecasts of the Executive Board as well as the information available to it to date, and have been made to the best of its knowledge and belief. No guarantee or liability for the occurrence of the future developments and results specified can be assumed in respect of such forward-looking statements. Rather, the future developments and results are dependent on a number of factors; they entail risks and uncertainties beyond our control and are based on assumptions which could prove to be incorrect. Notwithstanding any legal requirements to adjust forecasts, we assume no obligation to update the forward-looking statements contained in this presentation.

Interim financial reports as well as preliminaries are not audited.

Content



- 1. Highlights Q2 2013
- 2. Financials and Outlook
- 3. Appendix

Highlights Q2 2013



- Good organic sales development, but order entry lagging behind
- Similar demand structure as in Q1: healthy demand for Anesthesia, Monitoring, Hospital Consumables & Accessories; weaker demand in Workplace Infrastructure and Engineered Solutions
- Over-proportional expense growth, EBIT-margin at 7.0%
- Full year guidance confirmed
- Successful milestone in ERP program
- Update on products:
 - M540 "standalone" update
 - Bodyguard 1500




	Q2 2012	Q2 2013	Change	6M 2012	6M 2013	Change
	€ million	€ million	%	€ million	€ million	%
Order intake	588.4	588.5	0.01	1,139.3	1,159.8	+1.8 ¹
Order on hand				524.5	533.7	+1.81
Net sales	543.4	566.8	+4.31	1,072.7	1,100.6	+2.61
Gross margin	50.2 %	48.7 %		50.1 %	49.7 %	
EBIT	47.0	39.4	-16.0	93.7	79.2	-15.4
EBIT margin	8.6 %	7.0 %		8.7 %	7.2 %	
Income taxes	12.0	-10.3	-14.2	23.5	21.0	-10.6
Tax rate	30.2 %	31.1 %		30.6 %	31.6 %	
Earnings after income taxes	27.7	23.0	-17.1	53.2	45.6	-14.3
DVA	_			133.4	132.9	-0.4

¹ Currency adjusted: Q2 2013: order intake +2.1 %, net sales +6.5 %

6M 2013: order intake +3.2 %, orders on hand +4.1 %, net sales +4.2 %



Medical division: order entry in Q2 2013





Medical division


	Q2 2012	Q2 2013	Change	6M 2012	6M 2013	Change
	€ million	€ million	%	€ million	€ million	%
Order intake	387.1	385.4	-0.4 ¹	735.7	749.2	+1.8 1
Orders on hand				369.7	348.9	-5.6 ¹
Net sales	348.0	363.4	+4.4	685.7	704.4	+2.7
EBIT	32.2	25.6	-20.3	60.3	53.3	-11.6
EBIT margin	9.2 %	7.1 %		8.8 %	7.6 %	
DVA				133.5	125.7	-5.9

¹ Currency adjusted: Q2 2013: order intake +1.5 %, net sales +6.5 %

6M 2013: order intake +3.2 %, orders on hand -3.3%, net sales +4.3 %



Safety division: order entry in Q2 2013





Safety division

	Q2 2012	Q2 2013	Change	6M 2012	6M 2013	Change
	€ million	€ million	%	€ million	€ million	%
Order intake	209.6	210.7	+0.5 ¹	419.5	426.2	+1.6
Orders on hand				156.7	186.2	+18.9
Net sales	202.9	211.3	+4.1	402.4	412.0	+2.4
EBIT	24.8	21.8	-12.2	52.3	40.3	-23.0
EBIT margin	12.2 %	10.3 %		13.0 %	9.8 %	
DVA				64.2	66.2	+3.1

¹ Currency adjusted: Q2 2013: order intake +2.6 %, net sales +6.3 %

6M 2013: order intake +3.0 %, orders on hand +21.1 %, net sales +3.8 %

Key figures



	6M 2012	6M 2013	Change
	€ million	€ million	%
Cash flow from operating activities	48.7	-11.0	-122.6
Investments	33.9	43.5	+28.2
Cash and cash equivalents ¹	307.9	197.2	-36.0
Net financial debt ¹ Net financial debt ¹ /EBITDA ²	143.5	130.9 0.5	-8.8
Capital employed ¹ EBIT ² /Capital Employed (ROCE)	920.6 23.1 %	997.6 21.6 %	+8.4
Net working capital ¹	398.5	499.8	+25.4

¹ Values at due date

² EBITDA and accordingly EBIT of the last twelve months

Functional expenses



	Q2 2012	Q2 2013	Change	6M 2012	6M 2013	Change
	€ million	€ million	%	€ million	€ million	%
Research and development costs	47.6	51.6	+8.3	93.8	100.0	+6.6
in % of net sales	8.8 %	9.1 %		8.7 %	9.1 %	
Marketing and selling expenses	147.9	153.2	+3.6	289.5	302.8	+4.6
in % of net sales	27.2 %	27.0 %		27.0 %	27.5 %	
General administrative expenses	33.6	28.9	-14.1	64.0	63.0	-1.5
in % of net sales	6.2 %	5.1 %		6.0 %	5.7 %	
Expenses Total	227.5	235.3	+3.4	444.4	467.2	+5.1
in % of net sales	41.9 %	41.5 %		41.4 %	42.4 %	

Outlook and mid-term perspective



	2012	2013	Midterm 2018
Net sales	+5.2 % (currency adjusted +2.5 %)	2.0 % - 4.0 %	CAGR > 4 %
EBIT margin	9.7 %	8.0 % - 10.0 %	10.0 % - 12.0 %
Gross Margin	49.2 %	48.5 % - 49.5 %	
Cash flow conversion	77 % of EBIT	50 % - 70 % of EBIT	
Equity ratio	34.7 %	35 % – 38 %	

Appendix



- 1. Financial calendar
- 2. Contact

Financial calendar



March 12, 2012 Accounts press conference, Hamburg

Analysts' meeting, Frankfurt

May 2, 2012 Report for the first three months 2013

Conference call, Lübeck

May 3, 2012 Annual shareholders' meeting, Lübeck

August 1, 2012 Report for the first six months 2013

Conference call, Lübeck

October 31, 2012 Report for the first nine months 2013

Conference call, Lübeck

Contact



Melanie Kamann

Corporate Communications

Drägerwerk AG & Co. KGaA Moislinger Allee 53–55 23558 Lübeck, Germany

Tel +49 451 882-3998 Fax +49 451 882-3944 Mobile +49 170 8558152

melanie.kamann@draeger.com www.draeger.com

Thomas Fischler

Investor Relations

Drägerwerk AG & Co. KGaA Moislinger Allee 53–55 23558 Lübeck, Germany

Tel +49 451 882-2685 Fax +49 451 882-3296 Mobile +49 151 12245295

thomas.fischler@draeger.com www.draeger.com

Diversity at Dräger



WE DON'T JUST PAY LIP SERVICE
TO DIVERSITY. IT'S PART OF WHO WE ARE.

